Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $2.02 -7.34%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
NLY, CP, RUSHA, More
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
- Teradyne (TER) Tops Q1 EPS by 18c
- Alamos Gold (AGI) Misses Q1 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
